Article Explains How Cannabis Could Be the “Holy Grail” of Neurological Medicine

Medical Marijuana, Inc. (OTC: MJNA) announced today that its portfolio company Kannalife Sciences, Inc. (“Kannalife”) was the focus of a Forbes article that discussed Kannalife’s role in developing a pharmaceutical treatment for the degenerative brain disorder Chronic Traumatic Encephalopathy (CTE), a concussion-related disease that is pervasive among NFL players.

The July 22 Forbes article titled, ”NFL To Name New Medical Chief, Bringing Hope for Cannabis Concussion Treatment,” describes how bio-pharmaceutical and phyto-medical company Kannalife is conducting U.S. government-licensed research to determine the effects of cannabinoids on CTE and how such research could lead to major changes in how the NFL treats and prevents players’ brain injuries. The article also includes success stories from former NFL players who have used medical marijuana instead of addictive opioid painkillers to address their brain injury-related symptoms.

In the article, Kannalife co-founder Thoma Kikis cites the plethora of athletes, including girl soccer players, who could benefit from Kannalife’s research. “We want to be able to have a pharmaceutical product that’s available the moment an injury happens,” Kikis told Forbes. “It would be great if the parents know what they’re giving their children. That it’s provided by a doctor and not from a dispensary.”

Scientific research studies have found that cannabidiol (CBD) reduces brain swelling and neurological impairment following a traumatic brain injury, which in turn improves recovery. Kannalife currently holds two licenses with the U.S. National Institutes of Health for U.S. Patent 6,630,507 “Cannabinoids as Antioxidants and Neuroprotectants.” These licenses are currently in use by Kannalife to develop novel therapeutic drugs to treat CTE and hepatic encephalopathy (HE). While CBD from marijuana is tightly restricted, CBD found naturally in hemp is legal throughout all 50 states in the U.S.

“CTE can affect everybody from children who fall off their bikes, to combat veterans, to the professional NFL football players that were highlighted in this Forbes article,” said Medical Marijuana, Inc. CEO Dr. Stuart Titus.

“Each time a story is written on the positive effects of cannabinoid therapeutics, hemp and marijuana – as well as cannabis derivatives such as CBD – we are one step closer to ‘access for all’ to this powerful botantical and its chemistry,” added Dr. Titus. “We are grateful for news organizations that continue spreading the word about the medical benefits of cannabis, which has the potential to effectively treat or prevent CTE, and for our Kannalife researchers who are on the front lines developing cannabinoid-based therapeutics and solutions.”